Zynerba Pharmaceuticals, Inc.

LSE:0M40 Stock Report

Market Cap: US$65.6m

Zynerba Pharmaceuticals Valuation

Is 0M40 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Book vs Peers

  • Price-To-Book vs Industry

  • Price-To-Book vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 0M40 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 0M40 ($1.31) is trading below our estimate of fair value ($56.32)

Significantly Below Fair Value: 0M40 is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 0M40?

Key metric: As 0M40 is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for 0M40. This is calculated by dividing 0M40's market cap by their current book value.
What is 0M40's PB Ratio?
PB Ratio2.3x
BookUS$29.02m
Market CapUS$65.60m

Price to Book Ratio vs Peers

How does 0M40's PB Ratio compare to its peers?

The above table shows the PB ratio for 0M40 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PBEstimated GrowthMarket Cap
Peer Average9.4x
REDX Redx Pharma
17.4x-22.3%UK£58.3m
EAH ECO Animal Health Group
0.5x34.2%UK£43.4m
POLB Poolbeg Pharma
3.1x-12.9%UK£38.3m
SAR Sareum Holdings
16.5xn/aUK£34.9m
0M40 Zynerba Pharmaceuticals
2.3x67.2%US$65.6m

Price-To-Book vs Peers: 0M40 is good value based on its Price-To-Book Ratio (2.3x) compared to the peer average (12.8x).

Price to Book Ratio vs Industry

How does 0M40's PB Ratio compare vs other companies in the GB Pharmaceuticals Industry?

3 CompaniesPrice / BookEstimated GrowthMarket Cap
EAH ECO Animal Health Group
0.5x34.2%US$54.57m
OCTP Oxford Cannabinoid Technologies Holdings
0.6x15.1%US$1.60m
NFX Nuformix
0.1xn/aUS$561.90k
No more companies available in this PB range
0M40 2.3xIndustry Avg. 2.3xNo. of Companies3PB03.67.210.814.418+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Book vs Industry: 0M40 is good value based on its Price-To-Book Ratio (2.3x) compared to the UK Pharmaceuticals industry average (2.7x).

Price to Book Ratio vs Fair Ratio

What is 0M40's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

0M40 PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio2.3x
Fair PB Ration/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate 0M40's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst 0M40 forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Nov ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Oct ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Sep ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Aug ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Jul ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Jun ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
May ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Apr ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Mar ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Feb ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Jan ’25n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Dec ’24n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Nov ’24n/a
US$1.26
0%
11.6%US$1.40US$1.11n/a2
Oct ’24US$1.27
US$1.26
-1.0%
11.6%US$1.40US$1.11n/a2
Sep ’24US$1.32
US$1.26
-4.9%
11.6%US$1.40US$1.11n/a2
Aug ’24US$0.37
US$5.80
+1,473.9%
69.1%US$10.00US$0.40n/a3
Jul ’24n/a
US$5.80
0%
69.1%US$10.00US$0.40n/a3
Jun ’24US$0.34
US$5.10
+1,412.5%
72.1%US$10.00US$0.40n/a4
May ’24US$0.38
US$5.38
+1,313.4%
74.2%US$11.00US$0.50n/a4
Apr ’24US$0.43
US$5.38
+1,148.8%
74.2%US$11.00US$0.50n/a4
Mar ’24US$0.49
US$5.44
+999.2%
71.9%US$11.00US$0.76n/a4
Feb ’24US$0.57
US$5.44
+846.6%
71.9%US$11.00US$0.76n/a4
Jan ’24US$0.53
US$5.44
+936.2%
71.9%US$11.00US$0.76n/a4
Dec ’23US$0.58
US$6.44
+1,004.8%
57.9%US$11.00US$0.76n/a4
Nov ’23n/a
US$6.50
0%
56.0%US$11.00US$1.00n/a4

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Formycon

€848.4m

A biotechnology company, develops biosimilar drugs in Germany and Switzerland.

0W4N

€48.50

7D

4.3%

1Y

-21.3%

Regeneron Pharmaceuticals

US$80.6b

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide.

0R2M

US$749.75

7D

0.4%

1Y

-5.8%

Laboratorios Farmaceuticos Rovi

€3.2b

Engages in the research, development, manufacture, and marketing of pharmaceutical products in Spain and internationally.

0ILL

€63.05

7D

2.4%

1Y

12.5%